Verapamil increases the bactericidal activity of bedaquiline against mycobacterium tuberculosis in a mouse model

Antimicrobial Agents and Chemotherapy

Volumn 59, Issue 1, 2015, Pages 673-676

  Gupta, Shashank ^a,b   Tyagi, Seep ^a   Bishaia, William R ^a,b  

^a JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b HOWARD HUGHES MEDICAL INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BEDAQUILINE; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VERAPAMIL; CALCIUM CHANNEL BLOCKING AGENT; QUINOLINE DERIVATIVE; TUBERCULOSTATIC AGENT;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERICIDAL ACTIVITY; CONTROLLED STUDY; DRUG POTENTIATION; DRUG SCREENING; FEMALE; IN VITRO STUDY; IN VIVO STUDY; MONOTHERAPY; MOUSE; MYCOBACTERIUM TUBERCULOSIS; NONHUMAN; TREATMENT DURATION; TUBERCULOSIS; ANIMAL; BAGG ALBINO MOUSE; DISEASE MODEL; DRUG COMBINATION; DRUG EFFECTS; LUNG; MICROBIOLOGY; TUBERCULOSIS, PULMONARY;

ANIMALS; ANTITUBERCULAR AGENTS; CALCIUM CHANNEL BLOCKERS; DIARYLQUINOLINES; DISEASE MODELS, ANIMAL; DRUG SYNERGISM; DRUG THERAPY, COMBINATION; FEMALE; LUNG; MICE; MICE, INBRED BALB C; MYCOBACTERIUM TUBERCULOSIS; TUBERCULOSIS, PULMONARY; VERAPAMIL;

EID: 84920107783     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.04019-14     Document Type: Article

References (19)

1. U.S. Food and Drug Administration. 2013. FDA news release. U.S. Food and Drug Administration, Silver Spring, MD. www.fda.gov/NewsEvents /Newsroom/PressAnnouncements/ucm333695.htm.
2. Andries K, Verhasselt P, Guillemont J, Göhlmann HW, Neefs JM, Winkler H, Van Gestel J, Timmerman P, Zhu M, Lee E, Williams P, de Chaffoy D, Huitric E, Hoffner S, Cambau E, Truffot-Pernot C, Lounis N, Jarlier V. 2005. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 307:223-227. http://dx.doi.org/10 .1126/science.1106753.
3. Janssen Therapeutics. 2013. Sirturo product information for health care providers. Janssen Therapeutics, Titusville, NJ.
4. Mingote LR, Namutamba D, Apina F, Barnabas N, Contreras C, Elnour T, Frick MW, Lee C, Seaworth B, Shelly D, Skipper N, Dos Santos Filho ET. The use of bedaquiline in regimens to treat drugresistant and drug-susceptible tuberculosis: a perspective from tuber-culosis-affected communities. Lancet, in press. http://dx.doi.org/10 .1016/S0140-6736(14)60523-7.
5. Diacon AH, Pym A, Grobusch M, Patientia R, Rustomjee R, Page-Shipp L, Pistorius C, Krause R, Bogoshi M, Churchyard G, Venter A, Allen J, Palomino JC, De Marez T, van Heeswijk RP, Lounis N, Meyvisch P, Verbeeck J, Parys W, de Beule K, Andries K, Mc Neeley DF. 2009. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 360:2397-2405. http://dx.doi.org/10.1056/NEJMoa0808427.
6. da Silva PE, Von Groll A, Martin A, Palomino JC. 2011. Efflux as a mechanism for drug resistance in Mycobacterium tuberculosis. FEMS Immunol Med Microbiol 63:1-9. http://dx.doi.org/10.1111/j.1574-695X .2011.00831.x.
7. Louw GE, Warren RM, Gey van Pittius NC, Leon R, Jimenez A, Hernandez-Pando R, McEvoy CR, Grobbelaar M, Murray M, van Helden PD, Victor TC. 2011. Rifampicin reduces susceptibility to ofloxacin in rifampicin-resistant Mycobacterium tuberculosis through efflux.Am J Respir Crit Care Med 184:269-276. http://dx.doi.org/10.1164/rccm .201011-1924OC.
8. Adams KN, Takaki K, Connolly LE, Wiedenhoft H, Winglee K, Humbert O, Edelstein PH, Cosma CL, Ramakrishnan L. 2011. Drug tolerance in replicating mycobacteria mediated by a macrophage-induced efflux mechanism. Cell 145:39-53. http://dx.doi.org/10.1016/j.cell.2011.02.022.
9. Gupta S, Tyagi S, Almeida DV, Maiga MC, Ammerman NC, Bishai WR. 2013. Acceleration of tuberculosis treatment by adjunctive therapy with verapamil as an efflux inhibitor.AmJ Respir Crit Care Med 188:600-607. http://dx.doi.org/10.1164/rccm.201304-0650OC.
10. Gupta S, Cohen KA, Winglee K, Maiga M, Diarra B, Bishai WR. 2014. Efflux inhibition with verapamil potentiates bedaquiline in Mycobacterium tuberculosis. Antimicrob Agents Chemother 58:574-576. http://dx .doi.org/10.1128/AAC.01462-13.
11. Andries K, Villellas C, Coeck N, Thys K, Gevers T, Vranckx L, Lounis N, de Jong BC, Koul A. 2014. Acquired resistance of Mycobacterium tuberculosis to bedaquiline. PLoS One 9:e102135. http://dx.doi.org/10 .1371/journal.pone.0102135.
12. Diacon AH, Dawson R, Von Groote-Bidlingmaier F, Symons G, Venter A, Donald PR, Conradie A, Erondu N, Ginsberg AM, Egizi E, Winter H, Becker P, Mendel CM. 2013. Randomized dose-ranging study of the 14-day early bactericidal activity of bedaquiline (TMC207) in patients with sputum microscopy smear-positive pulmonary tuberculosis. Antimicrob Agents Chemother 57:2199-2203. http://dx.doi.org/10.1128 /AAC.02243-12.
13. Neal RA, van Bueren J, McCoy NG, Iwobi M. 1989. Reversal of drug resistance in Trypanosoma cruzi and Leishmania donovani by verapamil. Trans R Soc Trop Med Hyg 83:197-198. http://dx.doi.org/10.1016/0035 -9203(89)90642-1.
14. Martin SK, Oduola AM, Milhous WK. 1987. Reversal of chloroquine resistance in Plasmodium falciparum by verapamil. Science 235:899-901. http://dx.doi.org/10.1126/science.3544220.
15. Diacon AH, Donald PR, Pym A, Grobusch M, Patientia RF, Mahanyele R, Bantubani N, Narasimooloo R, De Marez T, van Heeswijk R, Lounis N, Meyvisch P, Andries K, McNeeley DF. 2012. Randomized pilot trial of eight weeks of bedaquiline (TMC207) treatment for multidrugresistant tuberculosis: long-term outcome, tolerability, and effect on emergence of drug resistance. Antimicrob Agents Chemother 56:3271-3276. http://dx.doi.org/10.1128/AAC.06126-11.
16. Johnston A, Burgess CD, Hamer J. 1981. Systemic availability of oral verapamil and effect on PR interval in man. Br J Clin Pharmacol 12:397-400. http://dx.doi.org/10.1111/j.1365-2125.1981.tb01233.x.
17. Oros A, Houtman MJ, Neco P, Gomez AM, Rajamani S, Oosterhoff P, Attevelt NJ, Beekman JD, van der Heyden MA, Ver Donck L, Belardinelli L, Richard S, Antoons G, Vos MA, CONTICA Investigators. 2010. Robust anti-arrhythmic efficacy of verapamil and flunarizine against dofetilide-induced TdP arrhythmias is based upon a shared and a different mode of action. Br J Pharmacol 161:162-175. http://dx.doi.org /10.1111/j.1476-5381.2010.00883.x.
18. Liao WB, Bullard MJ, Kuo CT, Hsiao CT, Chu PH, Chiang CW. 1996. Anticholinergic overdose induced torsade de pointes successfully treated with verapamil. Jpn Heart J 37:925-931. http://dx.doi.org/10 .1536/ihj.37.925.
19. Shimizu W, Ohe T, Kurita T, Kawade M, Arakaki Y, Aihara N, Kamakura S, Kamiya T, Shimomura K. 1995. Effects of verapamil and propranolol on early afterdepolarizations and ventricular arrhythmias induced by epinephrine in congenital long QT syndrome. JAmColl Cardiol 26:1299-1309. http://dx.doi.org/10.1016/0735-1097(95)00313-4.